30 results about "Brain natriuretic peptide" patented technology

The invention discloses a diluent for whole blood lateral immunochromatography detection as well as a preparation method and a detection method thereof, and belongs to the technical field of immunochromatography detection. The diluent solves the technical problems of unsmooth chromatography, background interference, poor stability of detection results and the like caused by red blood cells during direct detection of whole blood samples. The diluent comprises a buffer system, an osmotic pressure regulator glycine, a nonionic surfactant polysorbate, an erythrocyte aggregation inducer polyvinylpyrrolidone, a dynamic viscosity regulator trehalose, a blocking protein, a stabilizer combination L-methionine and L-histidine, and a composite formula of water. Red blood cells are effectively induced to gather and intercept on the sample pad through the synergistic effect of all the components, and meanwhile the stability of the chromatography process and the activity of the detection reagent are maintained. The diluent is mainly used for lateral immunochromatography quantitative detection of markers such as pro-enkephalin, C-reactive protein, cardiac troponin I or N-terminal pro-brain natriuretic peptide in a whole blood sample.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The invention relates to the technical field of biological medicines, and provides a method for reducing acetonitrile residues in a recombinant human brain natriuretic peptide stock solution, which comprises the following steps: sequentially carrying out purification chromatography and ultrafiltration treatment on the human brain natriuretic peptide stock solution; during purification chromatography, a mobile phase comprises a phase A and a phase B; the phase A is a mixed solution of citric acid and sodium citrate; and the phase B is a mixed solution of citric acid, sodium citrate and sodium chloride. A chromatographic system is utilized, the recombinant human brain natriuretic peptide is adsorbed on a chromatographic medium under a specific mobile phase condition, then the chromatographic medium is switched to a proper B-phase buffer solution for elution, and in the process, acetonitrile is effectively separated and removed due to the adsorption characteristic difference between the acetonitrile and the recombinant human brain natriuretic peptide on the chromatographic medium. According to the technical scheme, the problem that the residual amount of acetonitrile in the recombinant human brain natriuretic peptide stock solution in related technologies is large is solved.

The utility model provides a brain natriuretic peptide detection reagent card, which belongs to the technical field of medical instruments, aims to solve the problem that the service life of test paper is affected due to the fact that sunlight irradiates the test paper, and comprises a reagent detection main body, a detection friction block, a detection groove, a reagent notch, a reagent inclined plane, reagent detection paper, a detection covering mechanism and a detection protection mechanism, the detection friction block is fixedly connected to the upper end surface of the reagent detection main body; the detection groove is formed in the upper end surface of the reagent detection main body; the reagent notch is formed in the upper end surface of the reagent detection main body; the reagent slope is positioned on the upper end surface of the reagent notch; the reagent detection paper is fixedly connected inside the reagent detection main body; the detection covering mechanism is arranged on the upper end surface of the reagent detection main body; the detection protection mechanism is arranged in the reagent detection main body. According to the utility model, the service life of the reagent card is ensured by adopting the detection covering mechanism, and the reagent card is ensured to be used smoothly by adopting the detection protection mechanism.

Disclosed is a method for preparing Au-Ru nanoenzymes, with steps as: 1) dissolving HAuCl4 and ruthenium metal salt in solvent to obtain metal salt solution; 2) adding NAC and TA to the metal salt solution, mixing them uniformly to obtain mixture; 3) adding NaBH4 aqueous solution to the mixture, stirring to react at room temperature, then continuing to stir to react at 50° C.˜70° C.; after the reaction is finished, performing centrifuging, and the precipitate is lyophilized to obtain Au—Ru nanoenzymes. The present invention further discloses a method for preparing ATBMzyme nanoenzymes, specifically: adding EDC and NHS to Au—Ru nanoenzymes solution, stirring to react, then adding brain natriuretic peptide to the reaction system, continuing to stir to react; after the reaction is finished, performing centrifuging, and the precipitate is lyophilized to obtain ATBMzyme nanoenzymes.

The utility model discloses a multi-factor combined inspection kit for cardiovascular diseases. The multi-factor combined inspection kit comprises a reagent card and a sample treatment box, a uniform mixing cavity is formed in the sample treatment box, and a reagent card slot and a sample adding hole are formed in the sample treatment box; a sample treatment liquid is preloaded in a mixing cavity of the sample treatment box; the multiple factors comprise four factors, namely cardiac troponin I, peptidin, an amino-terminal brain natriuretic peptide precursor and a D-dimer; the reagent card comprises a bottom plate, a sample pad, a detection pad and a sample suction pad. The sample treating fluid contains a fluorescence-labeled specific detection antibody aiming at the four factors and a fluorescence-labeled quality control detection antibody. The kit can be used for quantitatively detecting four indexes of cardiac troponin, peptidin, amino-terminal brain natriuretic peptide precursor and D-dimer within 15 minutes at the same time, is simple to operate and accurate in result, and is suitable for outpatient and emergency treatment of hospitals and primary medical institutions.

The invention provides a dilated cardiomyopathy child death risk prediction method, system and device, and relates to the technical field of medical prediction models.The method comprises the steps that clinical data of a target dilated cardiomyopathy child patient are obtained and input into a pre-constructed nomogram prediction model, and death risk prediction results of the target dilated cardiomyopathy child patient at multiple time points in the future are output; the nomogram prediction model is constructed through independent prediction factors, the amino-terminal brain natriuretic peptide precursor level, the gender and the digoxin use condition which are determined through single-factor and multi-factor Cox regression analysis. According to the method, the nomogram prediction model is constructed by integrating the key clinical variables, accurate prediction and individualized treatment guidance of the dilated cardiomyopathy death risk of children are achieved, and the accuracy of clinical decision and the prognosis management effect are effectively improved.

To provide a method, a reagent and a kit for accurately measuring N-terminal pro-brain natriuretic peptide (NT-proBNP) in a sample with high sensitivity.SOLUTION: In a latex agglutination immunoassay method for NT-proBNP in a sample, N-terminal pro-brain natriuretic peptide (NT-proBNP) in the sample is reacted with latex particles to which an antibody recognizing NT-proBNP or an antibody fragment thereof is bonded in an aqueous medium in the presence of a pyridinium derivative.SELECTED DRAWING: None

The invention discloses a preparation method of glycosylated brain natriuretic peptide precursor protein, a brain natriuretic peptide quality control product, a kit and application of the brain natriuretic peptide quality control product. The preparation method comprises the following steps: inserting a target gene of the brain natriuretic peptide precursor protein into a plasmid to construct a recombinant expression vector; transforming the recombinant expression vector into pichia pastoris, performing fermentation culture, and collecting fermentation liquor; and purifying the fermentation liquor to obtain the glycosylated brain natriuretic peptide precursor protein. According to the preparation method, the expressed protein can be subjected to glycosylation modification by using a pichia pastoris expression system, and the expression quantity is high, so that the glycosylation ProBNP with a longer sequence and a longer half-life period is obtained, the problems that in a traditional BNP preparation process, the maturity of the protein expressed by escherichia coli is not high and the protein is different from a natural sample are solved, and the preparation method is suitable for industrial production. And the difficulty in process amplification of mammalian cell expression protein is also avoided.

The present invention relates to the field of biomedicine technology, and discloses a method for preparing Au-Ru nanozyme, comprising the steps of: 1) dissolving HAuCl4 and ruthenium metal salt in a solvent to obtain a metal salt solution; 2) adding NAC and TA to the metal salt solution, mixing uniformly, and obtaining a mixed solution; 3) adding a NaBH4 aqueous solution to the mixed solution, stirring the reaction at room temperature, and then continuing to stir the reaction at 50°C to 70°C; centrifuging after the reaction is completed, and freeze-drying the precipitate to obtain the Au-Ru nanozyme. The present invention also discloses a method for preparing ATBMzyme nanozyme, specifically: adding EDC and NHS to the Au-Ru nanozyme solution, stirring the reaction, and then adding brain natriuretic peptide to the reaction system, and continuing to stir the reaction; centrifuging after the reaction is completed, and freeze-drying the precipitate to obtain the ATBMzyme nanozyme. The Au-Ru nanozyme and ATBMzyme nanozyme prepared by the present invention can be used to prevent, alleviate or / and treat cardiac toxicity and cardiac damage caused by chemotherapeutic drugs, and do not affect the lethality of chemotherapeutic drugs to tumors, and do not affect the functions of other tissues, and have good safety.

The invention relates to the technical field of medicine, in particular to a composition containing an angiotensin II receptor blocker and application of the composition in heart disease dilation medicine. The composition comprises an angiotensin converting enzyme inhibitor and an angiotensin II receptor blocker, and a small dose of ACEI and a large dose of ARB are combined to be used for dilating the heart disease. The traditional Chinese medicine composition has excellent effects in the aspects of reducing the left ventricular end diastolic anterior-posterior diameter or left-right diameter, plasma brain natriuretic peptide precursor (NT-pro BNP) plasma level, pulmonary arterial pressure and left ventricular ejection fraction, does not influence the normal levels of physiological indexes such as blood potassium, serum creatinine, urea nitrogen, alanine aminotransferase (ALT) and asparaginic acid aminotransferase (AST), and can be used for preparing a medicine for treating the left ventricular end diastole. The medicine can be applied to heart disease dilation medicines.

The application relates to the technical field of immunochromatographic medical detection, in particular to a brain natriuretic peptide immunochromatographic test paper based on Yb 3+ core-shell shell upconversion nanocrystals, which comprises a PVC bottom plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad which are sequentially connected and pasted on the PVC bottom plate; the nitrocellulose membrane is provided with a detection line T line and a quality control line C line which are separated from each other; the combination pad is loaded with a fluorescent detection probe and a quality control probe. Through the construction of a core-shell shell structure and the directional control of an energy gradient, near-infrared luminescence is significantly enhanced, and high-sensitivity quantitative detection is realized. Therefore, the problems of complex operation, low sensitivity, easy interference of sample background and difficulty in realizing accurate quantification of traditional brain natriuretic peptide detection methods are solved.

The invention relates to the field of biomedicine, in particular to a construction method of an old patient postoperative serious complication risk probability prediction column graph model based on preoperative human N-terminal brain natriuretic peptide. According to the method, five independent risk factors related to the occurrence of the postoperative serious complications of the elderly patient are provided, and the risk probability prediction column graph model is constructed by using multi-factor logistic regression and is used for evaluating the risk of the postoperative serious complications of the elderly patient. The method comprises the following steps: firstly, collecting clinical data of an operation of an elderly patient; then risk factor screening is carried out through multi-single-factor logistic regression; then, ranking the risk factors according to importance by using an optimal subset regression method to obtain characteristic variables with relatively high prediction values; and finally, establishing a multi-factor logistic regression risk probability prediction model, and constructing a column graph according to the prediction model. According to the method, the occurrence risk of the postoperative serious complications of the elderly patient can be accurately predicted based on the pre-operative N-terminal brain natriuretic peptide, clinical doctors can be helped to recognize the high-risk elderly patient suffering from the postoperative serious complications in the early stage, the doctors are guided to conduct individualized intervention, and occurrence of the postoperative serious complications of the elderly patient is reduced.

The application discloses a kind of for brain natriuretic peptide precursor and electrochemical multimodal synergistic monitoring platform of troponin-I photoelectricity construction and detection method, belong to biomedical detection technical field.Sensor platform includes ITO glass substrate, in ITO glass substrate region I and region II, respectively with the sensor for NT-proBNP and cTnI detection;Sensor for NT-proBNP detection includes mesoporous silica nanosphere attached on ITO, on silica nanosphere, there is mercapto acetic acid coated cadmium sulfide quantum dots, on cadmium sulfide quantum dots, there is NT-proBNP detection probe connection;Sensor for cTnI detection includes mesoporous silica nanosphere attached on ITO, on silica nanosphere, there is gold nanoparticle, on gold nanoparticle, there is cTnI detection probe coupling.The application can realize multi-mode multi-analyte detection.

The invention discloses a cardiovascular and cerebrovascular disease screening system and method based on collaborative acquisition, relates to the technical field of screening data, and is used for solving the problem of triggering logic separation, completing preliminary screening according to a preset screening rule by calling family history information in an electronic health record, marking a target user and accessing a screening evaluation mechanism, and obtaining a screening result. If not, a risk mark is directly generated, carotid plaque ultrasonic imaging and hemodynamic monitoring are carried out on the target user, plaque density parameters are calculated and fused with hemodynamic data to form user state feature values, the user state feature values are classified as abnormal users, and blood samples are collected through a biological index calibration module; the erythrocyte distribution width and the brain natriuretic peptide hormone content are detected, the erythrocyte mutation rate is calculated, the brain natriuretic peptide is combined to generate the calibration proportion, the state characteristic value is corrected, the corrected characteristic value is formed and compared with the risk threshold value to generate the risk mark, the risk screening accuracy and sensitivity are improved, and the omission ratio and the misjudgment rate are reduced.

The invention discloses an antibody pair, a reagent and a method for detecting BNP (Brain Natriuretic Peptide), and relates to the field of immunodiagnosis. The antibody pair for detecting the BNP disclosed by the invention comprises the first antibody and the second antibody, and the reagent and the detection method based on the antibody combination can accurately detect the existence of the BNP.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being cMyBPC, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide (Brain natriuretic peptide type peptide), GDF-15 (Growth differentiation factor 15), ANG2 (Angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1), or a lipid biomarker, such as Cholesterol, LDL (Low Density Lipoprotein) or APOAT (Apolipoprotein A-1) comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being cMyBPC and a second biomarker selected from the group consisting of: a BMP10-type peptide, FGF23, a BNP-type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1, or a lipid biomarker, such as Cholesterol or LDL, or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

The utility model provides a brain natriuretic peptide detection test strip cutting device, and relates to the technical field of test strip cutting. Two sets of wall plates are fixed to the fixing frame, a rail plate is installed on the fixing frame through bolts, a middle base is installed on the rail plate through bolts, and lead screws are installed between the two sets of wall plates and the middle base through bearings. The tool apron can be easily moved to a required position only by unscrewing the bolt on the tool apron, after the tool apron is adjusted to a proper position, the blade is stably pressed on a test paper board by extending the third hydraulic rod, the hydraulic driving design ensures the stability and uniformity in the cutting process, and the cutting efficiency is improved. The cutting quality fluctuation caused by non-uniform manual pressure is avoided; the pressing roller is installed between the two sets of side plates through the bearing, the pressing roller exerts proper pressure on a test paper board under the tension effect of the tension spring, it is ensured that the paper board is fully leveled before being cut, and therefore cutting errors caused by unevenness of the paper board are avoided.

To provide a method, a reagent and a kit for accurately measuring N-terminal pro-brain natriuretic peptide (NT-proBNP) in a sample with high sensitivity.SOLUTION: A latex agglutination immunoassay for N-terminal pro-brain natriuretic peptide (NT-proBNP) in a sample, which comprises reacting NT-proBNP in the sample with latex particles to which antibodies or fragments thereof that recognize NT-proBNP are bound, wherein the reaction is carried out in an aqueous solvent having a pH of pH6. 0 or less.SELECTED DRAWING: None

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

To provide a method, a reagent and a kit for accurately measuring N-terminal pro-brain natriuretic peptide (NT-proBNP) in a sample with high sensitivity.SOLUTION: In a latex agglutination immunoassay method for NT-proBNP in a sample, N-terminal pro-brain natriuretic peptide (NT-proBNP) in the sample is reacted with latex particles to which an antibody recognizing NT-proBNP or an antibody fragment thereof is bonded in an aqueous medium in the presence of polyethylene glycol having an average molecular weight of 6,000 or less.SELECTED DRAWING: None

The invention discloses an application of a water-soluble fullerene nano material in preparation of a medicine for treating and / or relieving heart failure. The treatment and / or relief of heart failure is embodied in at least one of the following aspects: 1) improving the systolic function of the heart; (2) the increase of the brain natriuretic peptide precursor content caused by heart failure is reduced; (3) the content of Ca < 2 + > in the failure heart is reduced; 4) improving cardiac hypertrophy caused by heart failure; 5) inhibiting cardiac fibrosis caused by heart failure; 6) reducing the active oxygen level of a heart pathologic region; 7) inhibiting inflammation of the heart failure part; and 8) inhibiting pyroptosis, apoptosis and cardiac fibrosis of the heart failure part. In a coronary artery ligation post-myocardial infarction heart failure mouse model, the FPs can regulate redox balance in a pathological area, reduce excessive inflammation, pyroptosis, apoptosis, cardiac hypertrophy and fibrosis of a heart failure part and improve a mouse cardiac systolic function, shows a good treatment effect, and is an ideal medicine for treating heart failure.

The invention discloses application of salvianolic acid C in preparation of a medicine for preventing and treating heart failure. A plurality of in-vitro model results show that the salvianolic acid C can improve heart failure related indexes, increase the survival rate of myocardial cells and improve myocardial cell hypertrophy. In an in-vivo experiment, cardiac ultrasound shows that the salvianolic acid C plays a role in protecting functional impairment caused by heart failure and can improve the heart function of a mouse with heart failure to a certain extent, and HE and Masson staining results show that the salvianolic acid C can also protect the heart tissue structure and improve the pathological change of the heart tissue caused by heart failure, so that the salvianolic acid C can be used for treating heart failure. Serum biochemical results show that the salvianolic acid C has a down-regulation effect on the rise of lactic dehydrogenase (LDH), creatine kinase isoenzyme (CK-MB), cardiac troponin I (cTNI) and brain natriuretic peptide (BNP) caused by heart failure. The salvianolic acid C can be used as a medicine for preventing and treating heart failure, and has higher clinical application value and development prospect.

To provide a method, a reagent and a kit for accurately measuring N-terminal pro-brain natriuretic peptide (NT-proBNP) in a sample with high sensitivity.SOLUTION: In a latex agglutination immunoassay method for NT-proBNP in a sample, N-terminal pro-brain natriuretic peptide (NT-proBNP) in the sample is reacted with latex particles to which an antibody recognizing NT-proBNP or an antibody fragment thereof is bound in an aqueous medium in the presence of a reduced anti-IgM antibody.SELECTED DRAWING: None

The invention discloses a functional nucleic acid sensor for rapidly and efficiently detecting brain natriuretic peptide, which is characterized in that an aptamer with high affinity with BNP (brain natriuretic peptide) is screened out and modified on CuxNiyCo3-x-y-MOF to construct a biosensing system for detecting the brain natriuretic peptide. A catalytic site of the CuxNiyCo3-x-y-MOF is competitively regulated and controlled by specific binding of the BNP and Apt, when the brain natriuretic peptide and the aptamer are specifically bound, the Apt is stripped, a catalytic active site of the MOF is exposed, and then glucose is catalyzed to react. The change amount of glucose is detected by virtue of a glucometer, so that the concentration content of the brain natriuretic peptide can be detected. The sensor disclosed by the invention has the characteristics of simplicity in operation, rapidness in detection, low cost and the like, does not need complex pretreatment steps, is convenient to carry, and has important significance on clinical rapid detection of the brain natriuretic peptide and early diagnosis of cardiovascular diseases.

The invention discloses application of a flavonoid compound or pharmaceutically acceptable salt or solvate thereof in preparation of a medicine for preventing, delaying and / or treating myocardial injury and / or heart aging. The flavonoid compound has a structure as shown in a formula (I). The flavonoid compound can increase the activity of cardiac muscle cells, inhibit the active oxygen level of the cardiac muscle cells, reduce the aging positive rate of the cardiac muscle cells, relieve neutrophil infiltration and muscle fiber breakage of cardiac muscle tissues and reduce the expression level of brain natriuretic peptide (BNP) and troponin T (cTnT) in serum. (I)

This invention discloses a cardiovascular and cerebrovascular disease screening system and method based on collaborative data acquisition, belonging to the field of screening data technology. It addresses the problem of trigger logic separation by retrieving family history information from electronic health records, performing initial screening according to preset screening rules, marking target users and passing them into the screening assessment mechanism, while generating risk markers directly for non-target users. For target users, carotid artery plaque ultrasound imaging and hemodynamic monitoring are performed, plaque density parameters are calculated, and hemodynamic data are fused to form user status feature values. Users classified as abnormal undergo blood sample collection via a biometric calibration module to detect erythrocyte distribution width and brain natriuretic peptide (BNP) levels, calculate erythrocyte mutation rate, and combine it with BNP to generate a calibration ratio. The status feature values ​​are then corrected, forming corrected feature values ​​that are compared with a risk threshold to generate risk markers, improving the accuracy and sensitivity of risk screening and reducing false negative and false positive rates.

The invention provides an electrochemical method for detecting B-type brain natriuretic peptide or an N-terminal B-type brain natriuretic peptide precursor based on antigen-antibody recognition, which comprises the following steps: S1, electrode surface function modification: soaking an electrode in a modification solution containing a functional reagent, and reacting in a dark place at room temperature, or electrochemically depositing the functional reagent in the modification solution on the surface of the electrode to obtain a modified electrode surface; a functionally modified electrode is obtained; s2, antibody immobilization; s3, carrying out antigen-antibody mutual reaction to obtain antigens / antibodies / electrodes with different concentrations; and S4, electrochemical detection. Through the interaction of the functional reagent and the surface of the electrode, an electrode sensing interface which can be combined with an antibody and can resist non-specific adsorption of non-target molecules in a complex sample is constructed; the immobilized antibody and the target BNP or NT-proBNP are subjected to a specific recognition effect, and the target BNP or NT-proBNP of a sample is captured, so that the BNP or NT-proBNP is rapidly and sensitively detected without a label.